Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma

Bashir Omarjee
European Respiratory Journal 2016 48: PA4904; DOI: 10.1183/13993003.congress-2016.PA4904
Bashir Omarjee
1Cabinet Médical, Allergologie - Exploration Fonctionnelle Respiratoire et du Sommeil, Saint-Denis, Reunion
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

BACKGROUND: A number of asthmatic subjects still use oral corticosteroids despite the use of high dose inhaled corticosteroids (ICS), long-acting B2 agonists (LABAs) and antileukotrienes. The aim of the study was to evaluate the ability of Tiotropium, a long-acting antimuscarinic bronchodilator (LAMAs) as an add on therapy to high-dose ICS/LABA in patients requiring OCS for effective asthma control.

METHODS: For eligibility, patients, aged 20-50 years, were required to have had severe persistent asthma for at least 12 months before enrollment and they were required to have needed daily or alternate-day OCSs for asthma control for the last 6 months before enrollment. Of the 422 asthmatic patients, 33 (8%) patients not controlled on combined ICS/LABA needed OCSs were assigned to Tiotropium 5 ug group (n=12), the Tiotropium 2.5 ug group (n=10) and without Tiotropium group (n=11).

RESULTS: At the end point (12 weeks), Tiotropium 5ug and 2.5ug once daily reduced OCS requirements by 56.0% and 44.1% respectively, whereas patients without Tiotropium increased OCS requirements by 97%. Oral steroids were eliminated in 52%, 36% and 0% of patients in the Tiotropium 5ug and 2.5ug groups and without Tiotropium group, respectively. Tiotropium treatment produced significant increases in pulmonary function. Moreover, within-group comparisons revealed that FEV1 was significantly improved between baseline and endpoint in both active treatment groups despite reduce prednisone use.

CONCLUSION: Tiotropium is an effective alternative to systemic corticosteroids in patients with severe persistent asthma.

  • Treatments
  • Asthma - management
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma
Bashir Omarjee
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4904; DOI: 10.1183/13993003.congress-2016.PA4904

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma
Bashir Omarjee
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4904; DOI: 10.1183/13993003.congress-2016.PA4904
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Monitoring local pulmonary cAMP levels: Combining precision cut lung slice (PCLS) and fluorescence resonance energy transfer (FRET) technologies in mice
  • Olodaterol attenuates bleomycin induced lung fibrosis in mice
  • Prostacyclin IP receptor activation blocks hyperosmolar-induced bronchoconstriction in isolated human small airways
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society